Immune reconstitution disease associated with mycobacterial infections

Current Opinion in HIV and AIDS

Volumn 3, Issue 4, 2008, Pages 425-431

  Lawn, Stephen D ^a,b   Lipman, Marc C ^c   Easterbrook, Philippa J ^d,e  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d ST THOMAS HOSPITAL   (United Kingdom)

^e MAKERERE UNIVERSITY   (Uganda)

Author keywords

Antiretroviral; HAART; Immune reconstitution; IRIS; Mycobacter

Indexed keywords

BCG VACCINE;

ANTIVIRAL THERAPY; DISEASE ASSOCIATION; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFECTION RATE; INFECTION RISK; LEPROSY; MORTALITY; MYCOBACTERIOSIS; MYCOBACTERIUM LEPRAE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TUBERCULOSIS; VACCINATION REACTION;

EID: 67649613027     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3282fe99dc     Document Type: Review

References (62)

1. Egger M, MayM, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
2. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004; 18:1615-1627.
3. Shelburne SA III, Hamill RJ. The immune reconstitution inflammatory syndrome. AIDS Rev 2003; 5:67-79.
4. Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5:361-373.
5. Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005; 19:399-406.
6. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis 2006; 42:418-427.
7. Bourgarit A, Carcelain G, Martinez V, et al. Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS 2006; 20:F1-F7.
8. Ruhwald M, Ravn P. Immune reconstitution syndrome in tuberculosis and HIV-co-infected patients: Th1 explosion or cytokine storm? AIDS 2007; 21:882-884.
9. Wilkinson RJ. Pathogenesis of the HIV-TB associated immune reconstitution inflammatory syndrome [abstract]. In: Fourth International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention; 22-25 July 2007 Sydney. Geneva: IAS; 2007. Abstract MOBS202.
10. Simonney N, Dewulf G, Herrmann J, et al. AntiPGL-Tb1 responses as an indicator of the immune restoration syndrome in HIV-TB patients. Tuberculosis (in press). In this small study, cases of TB IRD were found to have unusually low baseline serum levels of anti-PGL-Tb1 antibodies prior to onset of IRD compared with TB patients who did not develop IRD. This outcome could be of prognostic value and may provide clues to underlying mechanisms.
11. Kestens L, Sediki N, Bohjanen P. The pathogenesis of immune reconstitution disease. Curr Opin HIV AIDS 2008; 3:000-000.
12. Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998; 158:157-161.
13. Breen RA, Smith CJ, Bettinson H, et al. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax 2004; 59:704-707.
14. Breton G, Duval X, Estellat C, et al. Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis 2004; 39:1709-1712.
15. Burman W, Weis S, Vernon A, et al. Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis. Int J Tuberc Lung Dis 2007; 11:1282-1289. This paper describes one of only a few cohort studies of TB IRD with a prospective design. Conducted in the USA, this study described the frequency and morbidity of TB IRD. A lower rate (15%) was observed compared with many other cohorts in high-income settings.
16. Kumarasamy N, Chaguturu S, Mayer KH, et al. Incidence of immune reconstitution syndrome in HIV/tuberculosis-coinfected patients after initiation of generic antiretroviral therapy in India. J Acquir Immune Defic Syndr 2004; 37:1574-1576.
17. Manosuthi W, Kiertiburanakul S, Phoorisri T, Sungkanuparph S. Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. J Infect 2006; 53:357-363.
18. Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21:335-341. This paper describes the first cohort study of TB patients in Africa reporting rates of TB IRD. The study highlighted the major importance of the timing of ART initiation during ART as a risk factor for development of IRD.
19. Serra FC, Hadad D, Orofino RL, Marinho F, et al. Immune reconstitution syndrome in patients treated for HIV and tuberculosis in Rio de Janeiro. Braz J Infect Dis 2007; 11:462-465. One of only four cohorts from resource-limited settings reported on rates of TB IRD (12% in this study).
20. Easterbrook PJ. HIV immune reconstitution syndrome in a sub-Saharan African setting. AIDS 2008; 22:643-645.
21. Perrin FM, Breen RA, Lipman MC. Is there a relationship between Mycobacterium tuberculosis strain type and TB paradoxical reaction? Thorax 2005; 60:706-707.
22. Dautremer J, Pacanowski J, Girard PM, et al. A new presentation of immune reconstitution inflammatory syndrome followed by a severe paradoxical reaction in an HIV-1-infected patient with tuberculous meningitis. AIDS 2007; 21:381-382. This report highlights the importance of TB IRD involving the central nervous system.
23. Lee CH, Lui CC, Liu JW. Immune reconstitution syndrome in a patient with AIDS with paradoxically deteriorating brain tuberculoma. AIDS Patient Care STDS 2007; 21:234-239.
24. Corti M, Palmero D, Trione N, et al. Cerebral abscess associated with multidrug-resistant tuberculosis and immune reconstitution. Int J Tuberc Lung Dis 2006; 10:1417.
25. Lawn SD, Wood R. Hepatic involvement with tuberculosis-associated immune reconstitution disease. AIDS 2007; 21:2362-2363. This report highlights the importance and manifestations of TB IRD involving the liver.
26. Lawn SD, Edwards DJ, Wood R. Concurrent drug therapy for tuberculosis and HIV infection in resource-limited settings: present status and future prospects. Future HIV Ther 2007; 1:387-398.
27. Schiffer JT, Sterling TR. Timing of antiretroviral therapy initiation in tuberculosis patients with AIDS: a decision analysis. J Acquir Immune Defic Syndr 2007; 44:229-234. This paper describes a hypothetical decision analysis concerning the optimal time to initiate ART in patients with TB. This analysis identifies the mortality associated with IRD and the mortality associated with delays in ART initiation as the two key competing variables that determine the optimal timing.
28. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817-824.
29. th February 2007; Los Angeles. Alexandria: CROI; Abstract 0-126.
30. Lawn SD, Wood R. When should antiretroviral treatment be started in patients with HIV-associated tuberculosis in South Africa? S Afr Med J 2007; 97:412-415.
31. Lawn SD, Wood R. Optimum time to initiate antiretroviral therapy in patients with HIV-associated tuberculosis: there may be more than one right answer. J Acquir Immune Defic Syndr 2007; 46:121-123.
32. Blanc FX, Havlir DV, Onyebujoh PC, et al. Treatment strategies for HIV-infected patients with tuberculosis: ongoing and planned clinical trials. J Infect Dis 2007; 196 (Suppl 1):S46-S51.
33. Goldsack NR, Allen S, Lipman MC. Adult respiratory distress syndrome as a severe immune reconstitution disease following the commencement of highly active antiretroviral therapy. Sex Transm Infect 2003; 79:337-338.
34. Breen RA, Smith CJ, Cropley I, et al. Does immune reconstitution syndrome promote active tuberculosis in patients receiving highly active antiretroviral therapy? AIDS 2005; 19:1201-1206.
35. Park WB, Choe PG, Jo JH, et al. Tuberculosis manifested by immune reconstitution inflammatory syndrome during HAART. AIDS 2007; 21:875-877.
36. Lawn SD, Myer L, Bekker LG, Wood R.Burden of tuberculosis in an antiretroviral treatment programmein sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006; 20:1605-1612.
37. Bonnet M, Pinoges L, Varaine F, et al. Tuberculosis after HAART initiation in HIV-positive patients from five countries with a high tuberculosis burden. AIDS 2006; 20:1275-1279.
38. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005; 19:2109-2116.
39. Moore D, Liechty C, Ekwaru P, et al. Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS 2007; 21:713-719.
40. Seyler C, Toure S, Messou E, et al. Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan. Am J Respir Crit Care Med 2005; 172:123-127.
41. Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother 2006; 57:167-170.
42. Lawn SD, Wilkinson RJ, Lipman MC, Wood R. Immune Reconstitution and 'Unmasking' of Tuberculosis during Antiretroviral Therapy. Am J Respir Crit Care Med 2008; 177:680-685. This review and opinion article proposes a conceptual framework to better understand 'unmasking' TB and 'unmasking TB IRD'.
43. Lawn SD, Wood C, Lockwood DN. Borderline tuberculoid leprosy: an immune reconstitution phenomenon in a human immunodeficiency virusinfected person. Clin Infect Dis 2003; 36:e5-e6.
44. Ustianowski AP, Lawn SD, Lockwood DN. Interactions between HIV infection and leprosy: a paradox. Lancet Infect Dis 2006; 6:350-360.
45. Martiniuk F, Rao SD, Rea TH, et al. Leprosy as immune reconstitution inflammatory syndrome in HIV-positive persons. Emerg Infect Dis 2008; 13:1438-1440.
46. Trindade MA, Manini MI, Masetti JH, et al. Leprosy and HIV co-infection in five patients. Lepr Rev 2005; 76:162-166.
47. Narang T, Dogra S, Kaur I. Borderline tuberculoid leprosy with type 1 reaction in an HIV patient: a phenomenon of immune reconstitution. Int J Lepr Other Mycobact Dis 2005; 73:203-205.
48. Singal A, Mehta S, Pandhi D. Immune reconstitution inflammatory syndrome in an HIV seropositive leprosy patient. Lepr Rev 2006; 77:76-80.
49. Talhari C, Machado PR, Ferreira LC, Talhari S. Shifting of the clinical spectrum of leprosy in an HIV-positive patient: a manifestation of immune reconstitution inflammatory syndrome? Lepr Rev 2007; 78:151-154.
50. Kharkar V, Bhor UH, Mahajan S, Khopkar U. Type I lepra reaction presenting as immune reconstitution inflammatory syndrome. Indian J Dermatol Venereol Leprol 2007; 73:253-256.
51. McNeil Jr DG. Worrisome new link: AIDS drugs and leprosy. New York Times, 24 October 2006. http://query.nytimes.com/search/query?d=nytdsection% 2b&o=e%2b&v=Health%2b&c=a%2b&query=Leprosy&date-select= full. [Accessed 3 April 2008]
52. Lawn SD, Lockwood DN. Leprosy after starting antiretroviral treatment. BMJ 2007; 334:217-218.
53. Puthanakit T, Oberdorfer P, Punjaisee S, et al. Immune reconstitution syndrome due to bacillus Calmette-Guerin after initiation of antiretroviral therapy in children with HIV infection. Clin Infect Dis 2005; 41:1049-1052.
54. Siberry GK, Tessema S. Immune reconstitution syndrome precipitated by bacille Calmette Guerin after initiation of antiretroviral therapy. Pediatr Infect Dis J 2006; 25:648-649.
55. Hesseling AC, Marais BJ, Gie RP, et al. The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine 2007; 25:14-18.
56. Kroidl A, Huck K, Weinspach S, et al. Immune reconstitution inflammatory syndrome (IRIS) due to Bacille Calmette Guerin (BCG) in an HIV-positive child. Scand J Infect Dis 2006; 38:716-718.
57. Alexander A, Rode H. Adverse reactions to the Bacillus Calmette-Guerin vaccine in HIV-positive infants. J Pediatr Surg 2007; 42:549-552. This paper describes the largest case series of BCG IRD reported to date from a South African referral hospital. The difficulties regarding the surgical management are discussed.
58. Hesseling AC, Schaaf HS, Hanekom WA, et al. Danish bacille Calmette-Guerin vaccine-induced disease in human immunodeficiency virus-infected children. Clin Infect Dis 2003; 37:1226-1233.
59. Phillips P, Bonner S, Gataric N, et al. Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up. Clin Infect Dis 2005; 41:1483-1497.
60. Riddell J, Kaul DR, Karakousis PC, et al. Mycobacterium avium complex immune reconstitution inflammatory syndrome: Long term outcomes. J Transl Med 2007; 5:50.
61. Puthanakit T, Aurpibul L, Oberdorfer P, et al. Hospitalization and mortality among HIV-infected children after receiving highly active antiretroviral therapy. Clin Infect Dis 2007; 44:599-604. Mycobacterial IRD (both tuberculous and nontuberculous) was a key cause of hospital admission in this Thai cohort of children starting ART.
62. Puthanakit T, Oberdorfer P, Ukarapol N, et al. Immune reconstitution syndrome from nontuberculous mycobacterial infection after initiation of antiretroviral therapy in children with HIV infection. Pediatr Infect Dis J 2006; 25:645-648.